Lean body mass wasting and toxicity in early breast cancer patients receiving anthracyclines
Background: Sarcopenia refers to the reduction of both volume and number of skeletal muscle fibers. Lean body mass loss is associated with survival, quality of life and tolerance to treatment in cancer patients. The aim of our study is to analyse the association between toxicities and sarcopenia in early breast cancer patients receiving adjuvant treatment. Materials and Methods: Breast cancer patients who have received anthracyclinebased adjuvant treatment were retrospectively enrolled.